Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

Cipher Pharma -- CPH.T

Discussion in 'Canadian Stocks Message Boards' started by Biotechmaster, Mar 22, 2019.

  1. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    211
    Likes Received:
    5
    Undiscovered and Profitable Biotech with significant upside potential ..Many new attractive Product launches and approvals expected within this year . TGT $10+


    Cipher Pharmaceuticals (CPH.T)

    Market Cap: $39.7 Million CAD
    Cash $10.4 Million CAD
    Price: $1.46

    Shares Out: 26.8 Million


    Slide Presentation

    https://filecache.investorroom.com/mr5ircnw_cipher/204/Cipher Presentation Novembe 19 Final.pdf

    Cipher anticipates several key milestones in 2019 that will continue to enhance long term value, including:

    Xydalba launch in first half of 2019

    DTR-001 pre-clinical results in Q2 2019

    Regulatory approval for plecanatide from Health Canada in Q4 2019

    Regulatory approval for A-101 from Health Canada in Q4 2019

    Top line results for MOB-015 Phase 3 study in North America expected in late Q4 2019



    Largest Shareholder :

    John Douglas Mull, MD 9,911,265
    Grandeur Peak Global Advisors LLC 1,522,200
    Taylor Asset Management, Inc. (Canada) 243,100
    Harold Morton Wolkin, CFA 184,134
    Arthur M. Deboeck 104,300
    Mark A. Beaudet 87,790
    Christian Godin 39,009
    Robert D. Tessarolo 37,013
    Stephen L. Lemieux, CPA 25,008
    Acadian Asset Management LLC 9,093

    [​IMG]
     
  2. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    211
    Likes Received:
    5
  3. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    211
    Likes Received:
    5
    Strong insider buying in last days and many big milestones coming before year end ..Great buying opportunity here

    https://www.canadianinsider.com/node/7?menu_tickersearch=CPH+|+Cipher+Pharmaceuticals

    Cipher anticipates several key milestones in 2019 that will continue the growth of its Canadian commercial platform, including:

    *Regulatory approval for plecanatide from Health Canada in Q4 2019

    *Regulatory approval for A-101 from Health Canada in Q4 2019

    *Commercial launch of XYDALBA (dalbavancin)

    *North American top line results for MOB-015 in Q4 2019
     
  4. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    211
    Likes Received:
    5
    Both attractive drugs below could be approved by health canada within next month which could push this low float stock significantly higher ...

    Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada....Dec. 18, 2018
    https://cipher.investorroom.com/201...Solution-Accepted-for-Review-by-Health-Canada


    Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada....Dec. 17, 2018
    https://cipher.investorroom.com/201...CANATIDE-Accepted-for-Review-by-Health-Canada
     
  5. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    211
    Likes Received:
    5
    3-4 Weeks then drug approvals likely to come in .. this low float stock could double quickly.GL

    [​IMG]
     
  6. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    211
    Likes Received:
    5
    APPROVEEEEED

    Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)..Oct. 18, 2019
    https://finance.yahoo.com/news/cipher-pharmaceuticals-receives-health-canada-110000703.html

    It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months.According to IQVIA the total Canadian laxative and antispasmodic market (prescription and OTC) was valued at over CDN $200 million for the 12 months ending December 2018.

    Cipher acquired the Canadian rights to develop, market, distribute and sell TRULANCE® from Bausch Health Companies Inc.
     

Share This Page